<DOC>
	<DOC>NCT01809314</DOC>
	<brief_summary>This observational study will evaluate the efficacy and safety of epoetin beta (NeoRecormon) in participants with symptomatic anemia and cancer receiving chemotherapy. Participants receiving NeoRecormon once weekly in accordance with the Summary of Product Characteristics will be followed for 4 months.</brief_summary>
	<brief_title>An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adults greater than or equal to (â‰¥) 18 years of age Participants with solid tumors or lymphoproliferative disease Participants receiving chemotherapy Participants for whom erythropoietin is indicated for prestudy Hb level and observed anemic symptoms: Hb less than (&lt;) 11 g/dL or 6.83 millimoles per liter (mmol/L) ECOG performance status of 0, 1, or 2 Resistant hypertension Acute chronic bleeding within 3 months prior to study Iron deficiency that is unmanageable prior to study Hypersensitivity to the active substance or any of the excipients of the product Pregnant or breastfeeding women Epoetin treatment within 6 months prior to study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>